NEW YORK ( TheStreet) -- CHANGE IN RATINGSWalt Disney (DIS - Get Report) was upgraded at UBS to buy from neutral. Retrans/ reverse comp, accelerated return of capital, and parks profitability is underappreciated, UBS said. Price target is now $72.
LifePoint Hospitals (LPNT) was upgraded at UBS to buy from neutral at UBS. CMS proposed Medicare net IPPS was better than expected and should benefit the group, UBS said. Madison Square Garden (MSG - Get Report) was initiated with an outperform rating at Credit Suisse. $68 price target. Premium sports content is increasing in value, Credit Suisse said. NII Holdings (NIHD) upgraded at Wells Fargo to outperform from market perform. Estimates were also increased, as the company has multiple potential catalysts, Wells Fargo said. New York Times (NYT) was downgraded to hold at TheStreet Ratings. Park Electrochemical (PKE) was downgraded to hold at TheStreet Ratings. PVR Partners (PVR) was upgraded to buy at TheStreet Ratings. Simpson Manufacturing (SSD) was downgraded at DA Davidson to neutral from buy. $32 price target. Increased competition is facing increased competition, DA Davidson said.
Suntrust (STI - Get Report) was upgraded at FBR Capital Markets to outperform from market perform. $37 price target. Operating trends are improving, FBR Capital Markets said. Teledyne (TDY) was downgraded at Drexel Hamilton to hold from buy. $80 price target. Estimates also cut, as the company is seeing lower margins, Drexel Hamilton said. Tenet Healthcare (TCH) was upgraded at Robert Baird to outperform from neutral. $51 price target. Company should receive higher Medicare reimbursement rates, Baird said. Tenet Healthcare was upgraded at UBS to buy from neutral. CMS proposed Medicare net IPPS was better than expected and should benefit the group, UBS said.
Union Pacific (UNP - Get Report) was downgraded at TD Securities to hold from buy. Valuation call, based on a $161 price target, TD Securities said. STOCK COMMENTS/EPS CHANGES Allegheny (ATI) estimates, price target were increased at Keybanc. Estimates were boosted through 2014. Earnings momentum is bottoming, Keybanc said. Buy rating and new $40 price target.